NCT04611867 Study of PRO in Patients with Advanced Pancreatic or Biliary Tract Cancer (BetterEveryDay)
| NCT ID | NCT04611867 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Inna Chen, MD |
| Condition | Pancreatic Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 274 participants |
| Start Date | 2021-08-17 |
| Primary Completion | 2026-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 274 participants in total. It began in 2021-08-17 with a primary completion date of 2026-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Pancreatic and biliary tract cancer are ones of the leading causes of cancer-related deaths. During the course of illness, these patients often experience marked physical suffering, psychological distress and frequent unplanned resource-demanding hospitalized care. Patients with pancreatic and lung cancer have highest rates of unplanned hospitalizations. Investigator initiated prospective "Study of Supportive Application with Integrated Patient-Reported Outcomes in Patients with Advanced Pancreatic or Biliary Tract Cancer (BetterEveryDay)" is to be initiated based on the great need for optimizing treatment care, reducing hospitalizations and improving outcomes.
Eligibility Criteria
Inclusion Criteria: * Adult (aged 18 and over) * Confirmed by cytology or histology advanced lung (NSCLC) or pancreatic cancer * Written informed consent before any study procedures * Planning to receive 1st line systemic anticancer therapy within ≤2 weeks * Performance status: ECOG 0-2 * Access to the internet * Ability to read and respond to questions or able to complete questions with minimal assistance required from an interpreter or family member Exclusion Criteria: * No mobile device * Exhibiting signs of overt psychopathology or cognitive dysfunction * Any medical condition that the Investigator considers significant to compromise the safety of the patient or that impairs the interpretation of study assessments * Patient participating in another interventional study during the surveillance period. This is only relevant for studies that might interfere with the intervention. Participation in protocols related only to treatment will not preclude participation in the present study. Cases of doubt will be settled by the protocol responsible.
Contact & Investigator
Inna M Chen, MD
PRINCIPAL INVESTIGATOR
Herlev and Gentofte Hospital
Frequently Asked Questions
Who can join the NCT04611867 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pancreatic Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04611867 currently recruiting?
Yes, NCT04611867 is actively recruiting participants. Contact the research team at Inna.Chen@regionh.dk for enrollment information.
Where is the NCT04611867 trial being conducted?
This trial is being conducted at Herlev, Denmark.
Who is sponsoring the NCT04611867 clinical trial?
NCT04611867 is sponsored by Inna Chen, MD. The principal investigator is Inna M Chen, MD at Herlev and Gentofte Hospital. The trial plans to enroll 274 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.